MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

Home・Aandelen Lijst・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

513.79 -7.49

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

509.12

Max

518.5

Belangrijke statistieken
By Trading Economics
Inkomsten	-72M -114M
Verkoop	74M 287M
Winstmarge	-39.75
Werknemers	528
EBITDA	-68M -106M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+12.58% upside

Dividenden
By Dow Jones
Volgende Winsten	25 feb 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	4.2B 13B
Vorige openingsprijs	521.28
Vorige sluitingsprijs	513.79

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

263.2 / 277.1 Steun & Weerstand

Madrigal Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 jan 2026, 00:16 UTC

Acquisities, Fusies, Overnames

Edwards Lifesciences Drops Merger With JenaValve

10 jan 2026, 12:00 UTC

Acquisities, Fusies, Overnames

Copper Is the Prize in Mining Megadeals -- WSJ

10 jan 2026, 09:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

10 jan 2026, 09:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Basic Materials Roundup: Market Talk

10 jan 2026, 09:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

10 jan 2026, 09:00 UTC

Winsten

Big Banks Expected to Post Higher Profits as Shares Surge -- Barrons.com

9 jan 2026, 22:18 UTC

Marktinformatie

Changes Needed for Exxon Mobil to Return to Venezuela -- Market Talk

9 jan 2026, 21:50 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

9 jan 2026, 21:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Basic Materials Roundup: Market Talk

9 jan 2026, 21:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

9 jan 2026, 21:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

9 jan 2026, 21:43 UTC

Winsten

Acquisities, Fusies, Overnames

These Stocks Moved the Most Today: Oklo, Vistra, Opendoor, Intel, GM, Revolution Medicines, Tilray, and More -- Barrons.com

9 jan 2026, 20:39 UTC

Marktinformatie

GE Vernova Seen With Rising Concern of Overcapacity -- Market Talk

9 jan 2026, 20:38 UTC

Marktinformatie

U.S. Natural Gas Falls on Loose Supply Outlook -- Market Talk

9 jan 2026, 20:36 UTC

Acquisities, Fusies, Overnames

Cathie Wood's ARK Invest Takes a New Stake in Broadcom -- and Sold Another Hot Stock -- Barrons.com

9 jan 2026, 20:30 UTC

Marktinformatie

Oil Makes Weekly Gains in Geopolitically Driven Trade -- Market Talk

9 jan 2026, 20:15 UTC

Marktinformatie

Chevron Seen With Modest Opportunity to Boost Venezuela Oil Production -- Market Talk

9 jan 2026, 20:07 UTC

Marktinformatie

Global Equities Roundup: Market Talk

9 jan 2026, 20:07 UTC

Marktinformatie

Goldman Sachs' Pivot from Consumer Lending Seen as Positive -- Market Talk

9 jan 2026, 19:58 UTC

Acquisities, Fusies, Overnames

Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

9 jan 2026, 19:42 UTC

Marktinformatie

Adobe Seen With Weak Competitive Position Compared to Rivals -- Market Talk

9 jan 2026, 19:38 UTC

Acquisities, Fusies, Overnames

Wolters Kluwer Acquires StandardFusion >WTKWY

9 jan 2026, 19:31 UTC

Winsten

Qualcomm Stock Falls After Downgrade. The Apple Supplier Has an iPhone Problem. -- Barrons.com

9 jan 2026, 19:28 UTC

Winsten

Apple Stock Set to Break Brutal Losing Streak. Why It Remains Evercore's 'Top Pick.' -- Barrons.com

9 jan 2026, 18:30 UTC

Marktinformatie

U.S. Oil Rig Count Falls by 3 to 409 -- Market Talk

9 jan 2026, 18:23 UTC

Marktinformatie

Reports of Canada Oil Sector's Demise Are Premature -- Market Talk

9 jan 2026, 17:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Basic Materials Roundup: Market Talk

9 jan 2026, 17:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

9 jan 2026, 17:19 UTC

Marktinformatie

Energy Prices Not Seen Supporting More Drilling -- Market Talk

9 jan 2026, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Madrigal Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

12.58% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 626.22 USD 12.58%

Hoogste 900 USD

Laagste 527 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Madrigal Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Gebaseerd op 12 analisten die aandelenratings hebben gegeven aan Madrigal Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

263.2 / 277.1Steun & Weerstand

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.